Huber S, Lucas Z J
Int J Cancer. 1979 Feb;23(2):224-32. doi: 10.1002/ijc.2910230214.
Specific inhibition of cell-mediated cytotoxicity can be used as a quantitative measure of soluble tumor antigen if highly cytolytic cells are obtained. In vitro secondary stimulation of spleen cells sensitized in vivo to the syngeneic 13762A mammary adenocarcinoma results in a lymphocyte population consistently more cytolytic than lymphocytes after primary stimulation. Maximal cytolysis requires removal of dead lymphocytes from the effector population. Soluble tumor antigen (STA) is detected only in supernatants of 13762A mammary tumor cultures grown in the presence of the proteolytic enzyme inhibitor, epsilon-amino caproic acid. Soluble MTM antigen preparations block lymphocytes immune to the mammary tumor but not lymphocytes immune to a second mammary adenocarcinoma (R3230) or to allogeneic spleen cells. Soluble antigen preparations from other tumors do not inhibit lymphocytes specifically cytolytic to the 13762A tumor. Additional evidence that the STA preparation contains tumor antigen is its ability to induce specific cytolytic lymphocytes and partial protection from challenge with live MTA tumor cells.
如果能获得高细胞毒性的细胞，细胞介导的细胞毒性的特异性抑制可用作可溶性肿瘤抗原的定量指标。对同基因13762A乳腺腺癌进行体内致敏的脾细胞在体外进行二次刺激，会产生一个淋巴细胞群体，其细胞毒性始终高于初次刺激后的淋巴细胞。最大细胞溶解作用需要从效应细胞群体中去除死亡的淋巴细胞。可溶性肿瘤抗原（STA）仅在存在蛋白水解酶抑制剂ε-氨基己酸的情况下培养的13762A乳腺肿瘤培养上清液中检测到。可溶性MTM抗原制剂可阻断对乳腺肿瘤免疫的淋巴细胞，但不能阻断对第二种乳腺腺癌（R3230）或同种异体脾细胞免疫的淋巴细胞。来自其他肿瘤的可溶性抗原制剂不会抑制对13762A肿瘤具有特异性细胞毒性的淋巴细胞。STA制剂含有肿瘤抗原的额外证据是其诱导特异性细胞毒性淋巴细胞的能力以及对活MTA肿瘤细胞攻击的部分保护作用。
